The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adaptimmune Therapeutics plc Sponsored ADS 00653A107   1,152,880 4,809,677 SH   SOLE   4,809,677 0 0
Dyne Therapeutics, Inc. Common 26818M108   6,496,220 682,376 SH   SOLE   682,376 0 0
Entrada Therapeutics, Inc. Common 29384C108   29,440,737 4,381,062 SH   SOLE   4,381,062 0 0
Repare Therapeutics, Inc. Common 760273102   1,558,632 1,121,318 SH   SOLE   1,121,318 0 0
Werewolf Therapeutics, Inc. Common 95075A107   4,697,747 4,309,860 SH   SOLE   4,309,860 0 0